Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.
Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). Borbath I, et al. Among authors: pape uf. J Neuroendocrinol. 2022 Mar;34(3):e13105. doi: 10.1111/jne.13105. Epub 2022 Mar 1. J Neuroendocrinol. 2022. PMID: 35233848 Review.
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B; International Lanreotide and Interferon Alfa Study Group. Faiss S, et al. Among authors: pape uf. J Clin Oncol. 2003 Jul 15;21(14):2689-96. doi: 10.1200/JCO.2003.12.142. J Clin Oncol. 2003. PMID: 12860945 Clinical Trial.
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R; PROMID Study Group. Rinke A, et al. Among authors: pape uf. J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers.
O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. O'Toole D, et al. Among authors: pape uf. Neuroendocrinology. 2009;90(2):194-202. doi: 10.1159/000225948. Epub 2009 Aug 28. Neuroendocrinology. 2009. PMID: 19713711 Free article. No abstract available.
143 results